In last trading session, Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) saw 1,409,221 shares changing hands with its beta currently measuring 1.61. Company’s recent per share price level of $9.97 trading at $1.35 or 15.66% at ring of the bell on the day assigns it a market valuation of $282.63 Million. That closing price of EIGR’s stock is at a discount of -58.68% from its 52-week high price of $15.82 and is indicating a premium of 54.36% from its 52-week low price of $4.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 312.16 Million shares which gives us an average trading volume of 477.36 Million if we extend that period to 3-months.
For Eiger BioPharmaceuticals, Inc. (EIGR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1. Splitting up the data highlights that, out of 6 analysts covering the stock, none rated the stock as a Sell while 1 recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 5 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.59 in the current quarter.
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) trade information
Upright in the green today for gaining 15.66%, in the last five days EIGR remained trading in the green while hitting it’s week-highest on Thursday, Oct 15 when the stock touched $10.40- price level, adding 4.52% to its value on the day. Eiger BioPharmaceuticals, Inc.’s shares saw a change of -33.36% in year-to-date performance and have moved 18.5% in past 5-day. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) showed a performance of -0.1% in past 30-days. Number of shares sold short was 1.38 Million shares which calculate 0 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $34.17 to the stock, which implies a rise of 242.73% to its current value. Analysts have been projecting $23 as a low price target for the stock while placing it at a high target of $55. It follows that stock’s current price would jump +451.65% in reaching the projected high whereas dropping to the targeted low would mean a loss of 130.69% for stock’s current value.
Eiger BioPharmaceuticals, Inc. (EIGR) estimates and forecasts
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.6 Million for the same. And 5 analysts are in estimates of company making revenue of $23.33 Million in the next quarter that will end in December 01, 2020.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 17% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 19.3% while estimates for its earnings growth in next 5 years are of 0%
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)’s Major holders
Insiders are in possession of 1.7% of company’s total shares while institution are holding 85.05% percent of that, with stock having share float percentage of 86.52%. Investors also watch the number of corporate investors in a company very closely, which is 138 institutions for Eiger BioPharmaceuticals, Inc. that are currently holding shares of the company. 683 Capital Management LLC is the top institutional holder at EIGR for having 2.16 Million shares of worth $20.71 Million. And as of June 29, 2020, it was holding 7.38% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 1.97 Million shares on June 29, 2020. The number of shares represents firm’s hold over 6.73% of outstanding shares, having a total worth of $18.89 Million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 778377 shares of worth $7.47 Million or 2.66% of the total outstanding shares. The later fund manager was in possession of 520.12 Thousand shares on August 30, 2020, making its stake of worth around $5.81 Million in the company or a holder of 1.78% of company’s stock.